| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Zedoarondiol does not have a well-defined single protein target. It is known to inhibit the activation of the NF-kappaB signaling pathway, reducing the production of pro-inflammatory cytokines. It also modulates the MAPK signaling pathway and exhibits antioxidant activity by reducing the generation of reactive oxygen species (ROS).
|
|---|---|
| ln Vitro |
Zedoarondiol (5–20 μg/mL) can limit the production of MDA and ROS, decrease HUVEC damage, increase SOD activity, and prevent oxidatively caused damage. In HUVEC, there is minimal density of IL-1β, TNF-α, and MCP-1 protein expression and secretion. ox-LDL, or lipoprotein [1]. Curcuma diol increases the expression of nuclear HO-1, NQO1, and Nrf2 and causes the translocation of nuclear Nrf2 from the cytoplasm to the nucleus [1]. Zedoarondiol causes cell cycle arrest in the G0/G1 phase and inhibits the proliferation and DNA synthesis of vascular smooth muscle cells (VSMCs) stimulated by PDGF-BB. Zedoarondiol can also decrease the expression of CDK2 and cyclin E, activate AMPK and ACC, and block the phosphorylation of mTOR and p70S6K [1]. It can also raise the expression of p53 and p21.
Zedoarondiol demonstrates significant anti-inflammatory activity in vitro by inhibiting the lipopolysaccharide (LPS)-induced production of nitric oxide (NO), prostaglandin E2 (PGE2), TNF-alpha, and IL-6 in macrophages. It also reduces the expression of iNOS and COX-2 enzymes. It exhibits moderate antioxidant activity by scavenging DPPH radicals. |
| ln Vivo |
Dedicated in vivo efficacy studies have shown that zedoarondiol possesses anti-inflammatory activity in animal models. It has been reported to reduce ear edema in mice and to inhibit the production of inflammatory mediators in carrageenan-induced paw edema models. Its neuroprotective effects have been observed in models of cerebral ischemia.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typical for this natural product. Instead, pathway activity is assessed. The inhibition of NF-kappaB activation is measured using a luciferase reporter assay. iNOS and COX-2 protein levels are measured by Western blot. NO production is measured by the Griess reagent assay.
|
| Cell Assay |
Macrophage cell lines (e.g., RAW 264.7) are cultured and pre-treated with zedoarondiol (typically 1-50 uM) followed by stimulation with lipopolysaccharide (LPS) to induce inflammation. Nitric oxide levels in culture supernatants are measured by the Griess assay. Pro-inflammatory cytokine (TNF-alpha, IL-6) levels are measured by ELISA. iNOS and COX-2 expression is assessed by Western blot.
|
| Animal Protocol |
In rodent models of inflammation, such as carrageenan-induced paw edema, zedoarondiol is administered intraperitoneally at doses of 10-50 mg/kg prior to carrageenan injection. Paw swelling is measured using a plethysmometer. In models of neuroprotection, the compound is administered prior to induction of cerebral ischemia, and infarct volume is measured by TTC staining.
|
| ADME/Pharmacokinetics |
Detailed PK parameters for zedoarondiol are not extensively documented. As a natural product with a molecular weight of 284.35 g/mol and moderate lipophilicity, it is expected to have reasonable oral bioavailability. Comprehensive ADME studies have not been publicly reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for zedoarondiol are limited. As a constituent of a medicinal plant used traditionally, it is considered to have a relatively low toxicity profile. Comprehensive acute and sub-chronic toxicity studies have not been publicly reported for the purified compound.
|
| References |
|
| Additional Infomation |
4,10-Epimecurdinyl has been reported to be found in turmeric, turmeric, and other organisms with available data.
Zedoarondiol is a natural product that serves as a research tool for studying the pharmacology of Curcuma species. It is used as an analytical reference standard for the quality control of zedoary and turmeric extracts. The compound is not an approved drug. |
| Molecular Formula |
C15H24O3
|
|---|---|
| Molecular Weight |
252.349265098572
|
| Exact Mass |
252.172
|
| CAS # |
98644-24-7
|
| PubChem CID |
24834047
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
396.8±42.0 °C at 760 mmHg
|
| Flash Point |
207.9±24.4 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.529
|
| LogP |
1.63
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
408
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(=C1C[C@H]2[C@@H](CC[C@@]2(C)O)[C@@](CC1=O)(C)O)C
|
| InChi Key |
TXIKNNOOLCGADE-OSRDXIQISA-N
|
| InChi Code |
InChI=1S/C15H24O3/c1-9(2)10-7-12-11(5-6-14(12,3)17)15(4,18)8-13(10)16/h11-12,17-18H,5-8H2,1-4H3/t11-,12+,14-,15+/m1/s1
|
| Chemical Name |
(3R,3aS,8S,8aR)-3,8-dihydroxy-3,8-dimethyl-5-propan-2-ylidene-1,2,3a,4,7,8a-hexahydroazulen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9628 mL | 19.8138 mL | 39.6275 mL | |
| 5 mM | 0.7926 mL | 3.9628 mL | 7.9255 mL | |
| 10 mM | 0.3963 mL | 1.9814 mL | 3.9628 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
